Teva To Present Data For AUSTEDO XR Extended-Release Tablets, AUSTEDO Tablets And UZEDY Extended-Release Injectable Suspension At Psych Congress 2023
Portfolio Pulse from Happy Mohamed
Teva Pharmaceuticals will present 16 data presentations at the Psych Congress 2023, including data for AUSTEDO, AUSTEDO XR, UZEDY, TV-44749, and AJOVY. The presentations will highlight real-world effectiveness and adherence of AUSTEDO, safety data for UZEDY, and results from the RISE and SHINE studies. Teva will also host a symposium to discuss the DECIDE study, which surveyed clinician perspectives on the use of long-acting injectable antipsychotics.
September 06, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Teva's presentations at the Psych Congress 2023 could potentially increase the visibility and credibility of its neuroscience portfolio, potentially leading to increased adoption and sales.
The presentations at the Psych Congress 2023 will provide Teva an opportunity to showcase the effectiveness and safety of its neuroscience products. This could potentially lead to increased adoption by clinicians, thereby driving sales. Furthermore, the discussion on the DECIDE study could help address barriers to the use of long-acting injectable antipsychotics, potentially leading to increased usage of Teva's UZEDY.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100